Articles

Alvotech To Be The Global Frontrunner For Stelara Biosimilars Following Approval Of Selarsdi In US

Pharmaceuticals / United States / Fri 19 Apr, 2024

Key View 

  • Alvotech will be the global frontrunner for ustekinumab biosimilars following its latest approval of Selarsdi in the US.  
  • Johnson & Johnson will delay new entrants with ongoing patent litigation settlements, although the 2024 and 2025 patent cliffs are quickly approaching.  
  • Stelara revenue will be impacted immediately following
Read More
Download Indicator Summary
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Clearbit Form
 

Thank you. Your download link will be emailed to you shortly.